How autism may stem from problems with prediction
A ‘predictive coding’ theory of autism suggests that many of the condition’s hallmark traits occur when sensory input overrides expectation in the brain. Yale researchers, Katarzyna Chawarska, James McPartland and Philip Corlett, are featured.Source: Spectrum
Multicenter Trial Management Unit Expands the Scope of Research at Yale
In the past, Yale investigators who led multicenter trials had to put together ad hoc study teams, relying on unconnected siloed services to carry out their research. At the end of these trials, these teams, which had compiled so much experience and knowledge, disbanded and their knowledge was lost. This system was inefficient and put Yale at a disadvantage when competing with other institutions for grants for multicenter studies.
Yale study: Social media boosts friendship quality in adolescents with autism spectrum disorder
A study by Yale Department of Psychiatry and Yale Child Study Center researchers found that adolescents with autism spectrum disorder (ASD) derive high friendship quality through their use of social media
Major autism study underway-Yale researchers leading the charge
A study that could transform the way autism is diagnosed, tracked and treated and the work is being done in New Haven. Yale researchers are leading the charge in the four year study – the largest autism study funded by National Institutes of Health.Source: WTNH News8
Outcomes Worse in Patients with Persistent Conduction Abnormalities after TAVR
Recent advances in TAVR have enabled lower-risk patients to benefit from this therapy. However, post-TAVR complications with the heart’s electrical impulses, known as conduction abnormalities, continue to undermine the next generation of valve repair devices.
Waterbury Black church leaders, Yale team up to dispel myths about COVID vaccine for communities of color, seniors
In Waterbury, an aggressive effort to take the COVID-19 vaccine to hard-to-reach communities embarked on another chapter Friday. This time, one of the city’s most popular Black churches engaged in something unique to shatter some vaccine myths.Source: WTNH
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.
COVID-19: Being a part of research to make a change
Much like the rest of the world, I have been very aware of just how serious the COVID-19 pandemic is--a health crisis in need of immediate action with African Americans dying at twice the rate and hospitalized at almost three times that of our white counterparts. So, when I was given the opportunity to participate in the vaccine trial to fight the SARS-CoV-2 virus, I knew right away that it was my inherent duty as a community leader to sign up. As a Yale Cultural Ambassador and pastor for Walter’s Memorial AME Zion Church, it felt like such a significant way to further encourage members of my community to participate right alongside me, to drive health equity in our own community and advance science at the same time.
Bishop Kenneth Monroe: Prostate Cancer Survivor "Facing Uncertainty through Faith"
It was in the year 2000 when the Rev. Dr. Kenneth Monroe, then-pastor of the Metropolitan AME Zion Church, Hartford, CT noticed the need for more frequent bathroom breaks. Moreover, he realized that it was important to tell his doctor as soon as possible. He went for a physical and a prostate cancer screening which showed that his PSA count was 12.8. His doctor referred him to an urologist who ordered a prostate biopsy. The tissue was positive for cancer.
COVID-19: Making a Difference, Together
Vanessa Clayton’s story about clinical trials participation differs from most, as she was first approached to participate by her husband, Reverend Elvin Clayton, the pastor of the Walters Memorial AME Zion Church in Bridgeport, Connecticut and Cultural Ambassador to clinical research at Yale. Like many people of color, Mrs. Clayton was worried about the disproportionate impact of the COVID-19 virus on black and brown individuals. When her husband told her about the Phase 3 randomized and placebo-controlled trial looking to test the safety, tolerability, and immunogenicity of the SARS CoV 2 RNA vaccine against COVID-19, she did not immediately say yes. She decided to do her own homework to understand the research and also wanted to discuss it with family members in the health profession. Ultimately, after speaking to the study PI, Dr. Onyema Ogbuagu, and reviewing the informed consent, she decided to join her husband and hundreds of other Connecticut residents enrolling in the trial.